AG
ACRS icon

Algert Global’s Aclaris Therapeutics ACRS Stock Holding History

Algert Global’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-65,630
Closed -$125K – 1122
2025
Q3 		$125K Buy
65,630
+25,780
+65% +$44.9K ﹤0.01% 1079
2025
Q2 		$57K Hold
39,850
– – ﹤0.01% 1158
2025
Q1 		$61K Buy
+39,850
New +$85K ﹤0.01% 1148
2024
Q4 		– Sell
-19,770
Closed -$23K – 1156
2024
Q3 		$23K Buy
19,770
+7,990
+68% +$9.8K ﹤0.01% 1147
2024
Q2 		$13K Sell
11,780
-4,021
-25% -$4.72K ﹤0.01% 1481
2024
Q1 		$20K Buy
+15,801
New +$18.8K ﹤0.01% 1050
2023
Q4 		– Sell
-45,120
Closed -$309K – 1113
2023
Q3 		$309K Buy
+45,120
New +$386K 0.01% 889
2023
Q2 		– Sell
-15,144
Closed -$123K – 1071
2023
Q1 		$123K Buy
15,144
+1,314
+10% +$16.7K 0.01% 1076
2022
Q4 		$218K Buy
+13,830
New +$222K 0.01% 995

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Algert Global's ACRS Position: Q4 2025 in Review

Algert Global sold out of Aclaris Therapeutics (ACRS) in Q4 2025, closing a stake of 65,630 shares — an estimated $125K sold.

Algert Global first reported a position in ACRS in Q4 2022 and held it in 9 quarters. The position peaked at $309K in Q3 2023. 122 funds tracked by Wall St. Rank hold ACRS as of Q4 2025.

  • Algert Global reported no remaining Aclaris Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Algert Global sold 65,630 Aclaris Therapeutics shares in Q4 2025, an estimated $125K.
  • Algert Global first reported a position in Aclaris Therapeutics in Q4 2022 and held it in 9 quarters.
  • Algert Global's Aclaris Therapeutics position peaked at $309K in Q3 2023.
  • 122 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q4 2025.

Based on Algert Global's 13F filing for Q4 2025, filed 17 Feb 2026.